Chengdu Origin Biotechnology

Chengdu Origin Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of innovative cell therapies for the treatment of solid tumors and hematological malignancies. The company leverages its proprietary technology platforms, including Ori-C1 and Ori-Ab, to engineer CAR-T cells with enhanced persistence and efficacy within the immunosuppressive tumor microenvironment. Its lead program, Ori-C101, is a GPC3-targeted CAR-T therapy currently in clinical trials for advanced hepatocellular carcinoma. Origin Biotechnology is committed to advancing next-generation immunotherapy solutions to address significant unmet needs in oncology through its robust pipeline of optimized immune cell products.